Quintiles receives Best Clinical Research Organization award
“We are honored to once again receive this prestigious award reflecting the insight of many from across the biopharmaceutical industry,” Phil Breitfeld, Quintiles vice president and head of the Therapeutic Centers of Excellence, said. “It is clear to us all that the health care industry has a tremendous opportunity to conquer the global burden of disease. We’re proud to be working alongside our customers to develop and commercialize vaccines and anti-infective products that contribute to those efforts and can help create a healthier world.”
The award recognizes individuals and companies for achievements and efforts within the vaccine industry. Leaders from the vaccine industry and biopharmaceutical companies select the Best CRO award winner in an online vote. The leaders choose their preferred provider before the start of the World Vaccine Congress.
The nominated companies must then pass the inspection of judges who grade the companies based on their range of services for core therapeutic and niche areas, their attention to the quality of their client relationships, their methods of introducing new services and improving current performance, their attainment of goals, their outcomes from striving for ongoing goals, and how they build and maintain long-term existing partnerships.
This is the third time in the past four years that Quintiles has received the award.
“We believe our extensive expertise in all phases of vaccine clinical trials, from early clinical development to real-world and late phase capabilities as well as commercial, advisory services and laboratory support helped garner this award,” Breitfeld said.
The award was given at the World Vaccine Congress 2015 in Washington, D.C. as part of the Vaccine Industry Excellence Awards.